AuraVax Therapeutics

AuraVax Therapeutics Inc. (“AuraVax”) is a privately held biotechnology company focused on developing proprietary and differentiated platforms for vaccines targeting various respiratory viruses, including COVID-19. Its next-generation vaccine platform combines the potential for home administration with the ability to provide full immunity. The technology has been validated for COVID-19 in initial animal studies and measures immunity through B-cell and T-cell responses.